June 6, 2025 DEL MAR, Calif. — Sydnexis‘ proprietary low-dose atropine formulation, SYD-101, has received marketing authorization from the European Commission (EC)....
April 2, 2025 DEL MAR, Calif. — Sydnexis has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human...
March 11, 2025 DEL MAR, Calif. — The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for...
July 16, 2024 DEL MAR, Calif. — Sydnexis has officially named a new Chief Executive Officer and member of the Board of...
SAN DIEGO — Sydnexis Inc., a clinical stage biopharmaceutical company focused on the treatment of progressive myopia in children and minimizing the...
sponsored content August 15, 2023 Myopia is the most common eye disease in children and has experienced a dramatic increase in prevalence...